AstraZeneca has announced a landmark $50 billion investment in the United States through 2030, a strategic initiative designed to significantly enhance America’s leadership in pharmaceutical innovation.
AstraZeneca announced groundbreaking results from its FLAURA2 Phase III trial, revealing that Tagrisso (osimertinib) combined with chemotherapy offers a statistically significant and clinically meaningful improvement in overall survival for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
AstraZeneca’s Datroway has received US FDA approval for advanced EGFR-mutated lung cancer. This first-in-class TROP2-directed therapy offers a vital new option for patients who have exhausted previous treatments.
AstraZeneca’s Calquence-based fixed-duration regimens gain EU approval for treating first-line CLL, offering patients a powerful, time-limited alternative to traditional continuous therapy.
The Phase III POTOMAC trial evaluated the effectiveness of Imfinzi in combination with BCG therapy compared to BCG therapy alone in patients with high-risk NMIBC.
The purpose of the duplicate, randomized, double-blind KALOS and LOGOS trials was to examine Breztri as a possible asthma medication.
Trial continues as planned to 52 weeks to further characterize the risk-benefit profile.
